The ATM gene and susceptibility to breast cancer : Analysis of 38 breast tumors reveals no evidence for mutation

• Published in: Cancer research (Chicago, Ill.) Vol. 56; no. 12; pp. 2726 - 2732
• Main Authors: VORECHOVSKY, I, RASIO, D, CROCE, C. M, NEGRINI, M, LUO, L, MONACO, C, HAMMARSTRÖM, L, WEBSTER, A. D. B, ZALOUDIK, J, BARBANTI-BRODANO, G, JAMES, M, RUSSO, G
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Association for Cancer Research 15-06-1996
• Subjects: Ataxia Telangiectasia - genetics; Base Sequence; Biological and medical sciences; Breast Neoplasms - genetics; Chromosomes, Human, Pair 11 - genetics; Disease Susceptibility; DNA Mutational Analysis; Female; Gene Deletion; Genes, Tumor Suppressor - genetics; Gynecology. Andrology. Obstetrics; Humans; Mammary gland diseases; Medical sciences; Medicin och hälsovetenskap; Middle Aged; Molecular Sequence Data; Polymerase Chain Reaction; Tumors; Human; Mammary gland diseases; Tissue; Pathogenesis; Predisposition; Deletion; Mammary gland; Mutation; Malignant tumor; Chromosome C11; Tumor suppressor gene
• ISSN: 0008-5472; 1538-7445

Heterozygosity for ataxia-telangiectasia (A-T), a cancer-prone recessive syndrome, has been associated with an increased risk of breast cancer. The gene for A-T (ATM) is located at chromosomal region 11q22-q23, a region of frequent loss of constitutional heterozygosity in breast and other tumors. Loss of constitutional heterozygosity at 1lq22-q23 was found in 47% of informative cases in the series of primary tumors analyzed in this study. To investigate the role of ATM in breast cancer, we have determined the complete genomic organization of the gene, developed an exon-scanning PCR single-strand conformation polymorphism (PCR-SSCP) assay for mutation detection of ATM, and screened 38 consecutive breast tumors for mutations using both genomic DNA- and cDNA-based assays. In addition to common ATM polymorphisms detected both in the coding sequence and in flanking introns, seven unique SSCP alleles were identified in six tumor DNAs. Sequence analysis of these alleles revealed rive nucleotide substitutions that were predicted to change the encoded amino acid. However, PCR-SSCP and nucleotide sequencing analysis of the paired blood samples and of an extended sample size of a total of 224 chromosomes indicated that these SSCP patterns represent constitutional rare polymorphisms with a frequency between 0.005 and 0.023. Because the majority of A-T mutations are null mutations and none of the ATM alleles found in breast cancer samples would lead to the truncation of the translation product, we conclude that, in this initial sample of sporadic breast cancer patients, there was no evidence for an increased number of A-T carriers. In addition, because no somatic mutations were found, our study rules out the ATM gene as the frequently altered tumor suppressor gene at 11q23.